In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Immunomedics, Inc.

http://www.immunomedics.com

Latest From Immunomedics, Inc.

AZ Bets Big On ADCs As It Inks Second, $6bn Deal With Daiichi

Following their original March 2019 tie-up for an oncology antibody-drug conjugate, Daiichi Sankyo and AstraZeneca have entered into a new global deal worth up to $6bn for a second novel asset from the Japanese firm, with potential in breast, lung and other cancers.

Commercial Deals

European OTC Results Round-Up: Boiron, Alliance Pharma and Karo

COVID-19 had a differing impact on Q2 consumer health sales for France's Boiron, the UK's Alliance Pharma and Sweden's Karo.

Sales & Earnings OTC Drugs

UK Marketing: Sanofi Launches Buscomint, New Releases From Salonpas and Nailner

The latest OTC launches in the UK, including Buscomint from Sanofi, Salonpas Gel-Patch from Hisamitsu and Nailner Active Cover from Karo.

Innovation Launches

Immunomedics’ ASCENT Confirms Trodelvy’s Efficacy In Triple-Negative Breast Cancer

After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.

Clinical Trials Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • IBC Pharmaceuticals, Inc.
UsernamePublicRestriction

Register